Menu
No results found.
AFP
AFT Pharmaceuticals Limited – ASX
Weekly Share Price & Valuation Overview
Market Overview
Open
2.4500
Close
2.4500
High
2.4500
Low
2.4500
Trend
0.35722
AFT Pharmaceuticals Limited
New Zealand
• ASX - Australian Securities Exchange
• AFP
• Currency: AUD
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development, marketing, and distribution of pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, pain management, skin care, vitamins, and supplements, as well as other products. The company has collaboration with Belgium's Hyloris Pharmaceuticals to develop a novel innovative injectable iron deficiency therapy. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
Key strengths
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
Potential weaknesses
- Negative free cash flow — operations may rely on external financing.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- AUD 250.63M
- Enterprise Value Operating value: market cap + total debt − cash.
- AUD 268.96M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- AUD 208.02M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- AUD 91.71M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- AUD 18.02M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- AUD 1.98
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 0.10
- Shares Outstanding
- 104.87M
- Float Shares
- 30.50M
- Implied Shares Outstanding
- 105.44M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
16.03%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
8.66%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
44.09%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
5.75%
- ROA Return on assets: net income ÷ total assets.
-
6.58%
- ROE Return on equity: net income ÷ shareholder equity.
-
12.33%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Year-over-year revenue growth.
-
8.50%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
17.80%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
2.60%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.25
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.31
- Total Cash Cash and equivalents.
- AUD 11.11M
- Total Debt Short + long-term interest-bearing debt.
- AUD 30.00M
- Net Debt Total debt − cash (negative = net cash).
- AUD 18.89M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 1.66
Cash Flow
Shown only when internally consistent; margins are TTM.
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- AUD 13.18M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- AUD -2.35M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
6.33%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-1.13%
- Cash Conversion (OpCF/EBITDA)
- 0.73
Sharemaestro House View
Confidence: 2
Sharemaestro internal conviction (0–3, higher is better).
Risk: 3
Sharemaestro internal risk profile (0–3, higher is safer).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
29.1%
Insiders
Shares held by company insiders (officers, directors).
78.1%
Institutions
Shares held by institutions (funds, pensions).
2.0%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
0.5%
Net Debt
Total debt − cash (negative = net cash).
AUD 18.89M
9.1% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
59
Methodology Notes
- Dividend Yield suppressed due to an anomalous value from the feed (>30%).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 10:03
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.